BioSpace News Archive

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent broad-spectrum PB2 inhibitor CC-42344 against pandemic and seasonal influenza A strains at the World Vaccine Congress West Coast.

Vittoria Biotherapeutics announced the presentations of abstracts authored by researchers at the University of Pennsylvania and a poster authored by the Company, at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, taking place from December 9-12th , 2023, in San Diego, California.

Arcutis Biotherapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis.

ProJenX today announced authorization of its clinical trial application (CTA) by Health Canada for study PRO-101, a global, hybrid Phase 1 clinical trial evaluating prosetin—a first-in-class MAP4K inhibitor—in healthy volunteers and participants with ALS.

Ferring Pharmaceuticals today announced the presentation of new 36-month follow-up data from the Phase 3 study at the 24th Annual Meeting of the Society of Urologic Oncology (SUO) demonstrating a sustained durability of response with ADSTILADRIN® (nadofaragene firadenovec-vncg) in adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1).

Nascent Biotech, Inc. is pleased to announce the Company has been issued a patent from the Japanese Patent Office for its primary asset, Pritumumab.

Oxford BioTherapeutics today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BI 764532.

Alpha Tau Medical Ltd. today announced that management will present at the Sidoti Small-Cap Virtual Conference on Thursday, December 7th, 2023.

Dyadic International, Inc. today announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine candidate, DYAI-100.

Intelligent Bio Solutions Inc. today announced that it will present at the Emerging Growth Conference on December 7, 2023.